Neubauer, Jonas http://orcid.org/0000-0002-4120-534X
Gklavas, Konstantinos
Kortüm, Friederike
Gosheva, Mariya
Bartz-Schmidt, Karl Ulrich
Ziemssen, Focke
Funding for this research was provided by:
Universitätsklinikum Tübingen
Article History
Received: 15 March 2022
Revised: 23 May 2022
Accepted: 12 July 2022
First Online: 6 August 2022
Declarations
:
: The study adhered to the tenets of the Declaration of Helsinki and was approved by the institutional ethics committee (Project Number 145/2022BO2).
: F. Z.: Consultant: Alimera Sciences, Allergan/Abbvie, Bayer, Boehringer-Ingelheim, Novartis, NovoNordisk, MSD, Oxurion, Roche/Genentech; Speaker: Alimera, Allergan/Abbvie, Bayer, BDI, CME Health, Gerling, Novartis, ODOS, Roche, Research: Bayer, BMBF, Clearside, DFG, Kodiak, Iveric, Ophtea, Novartis, Regeneron. All other authors declare they have no financial or direct/indirect competing interest.